Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines
In an earlier study, a novel Sendai virus–vectored anti-tuberculosis vaccine encoding Ag85A and Ag85B (SeV85AB) was constructed and shown to elicit antigen-specific T cell responses and protection against Mycobacterium tuberculosis (Mtb) infection in a murine model. In this study, we evaluate whether the immune responses induced by this novel vaccine might be elevated by a recombinant DNA vaccine expressing the same antigen in a heterologous prime-boost vaccination strategy. The results showed that both SeV85AB prime-DNA boost (SeV85AB-DNA) and DNA prime-SeV85AB boost (DNA-SeV85AB) vaccination strategies significantly enhanced the antigen-specific T cell responses induced by the separate vaccines. The SeV85AB-DNA immunization regimen induced higher levels of recall T cell responses after Mtb infection and conferred better immune protection compared with DNA-SeV85AB or a single immunization. Collectively, our study lends strong evidence that a DNA vaccine boost might be included in a novel SeV85AB immunization strategy designed to enhance the immune protection against Mtb.
A heterologous prime-boost regimen with a novel recombinant SeV85AB and a DNA vaccine increase the T cell responses above those from a single vaccine.
The heterologous prime-boost regimen provided protection against Mtb infection.
The DNA vaccine might be included in a novel SeV85AB immunization strategy designed to enhance the immune protection against Mtb.
KeywordsTuberculosis Sendai virus DNA vaccine Prime-boost T cell responses
This work was supported by grants from Chinese National Mega Science and Technology Program on Infectious Diseases (2018ZX10731301, 2018ZX10302301), the National Natural and Science Foundation of China (31771004, 81873884, 81501365, 81601735, 81770011), and the Shanghai Science and Technology Commission (19XD1403100, 17ZR1423900).
Compliance with ethical standards
Conflict of interest
X.Y.F., T.S., Z.D.H., and D.B.L. are co-inventors on an SeV85AB vaccine patent application.
All animal experiments were approved by the Institutional Animal Care and Use Committee and were performed according to the guidelines of the Laboratory Animal Ethical Board of Shanghai Public Health Clinical Center.
- 1.World Health Organization, Global tuberculosis report (2018) http://apps.who.int/medicinedocs/en/m/abstract/Js23553en/
- 13.Zhang X, Sobue T, Isshiki M, Makino S, Inoue M, Kato K, Shioda T, Ohashi T, Sato H, Komano J, Hanabusa H, Shida H (2012) Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm. PLoS One 7:e51633. https://doi.org/10.1371/journal.pone.0051633 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Moriya C, Horiba S, Inoue M, Iida A, Hara H, Shu T, Hasegawa M, Matano T (2008) Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of vector-specific neutralizing antibodies in rhesus macaques. Biochem Biophys Res Commun 371:850–854PubMedCrossRefGoogle Scholar
- 18.Hu Z, Wong KW, Zhao HM, Wen HL, Ji P, Ma H, Wu K, Lu SH, Li F, Li ZM, Shu T, Xu JQ, Lowrie DB, Fan XY (2017) Sendai virus mucosal vaccination establishes lung-resident memory CD8 T cell immunity and boosts BCG-primed protection against TB in mice. Mol Ther 25:1222–1233PubMedPubMedCentralCrossRefGoogle Scholar
- 23.Wu J, Ma H, Qu Q, Zhou WJ, Luo YP, Thangaraj H, Lowrie DB, Fan XY (2011) Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice. Vaccine 29:7624–7630PubMedCrossRefGoogle Scholar
- 24.Kang H, Yuan Q, Ma H, Hu ZD, Han DP, Wu K, Lowrie DB, Fan XY (2014) Enhanced protective efficacy against Mycobacterium tuberculosis afforded by BCG prime-DNA boost regimen in an early challenge mouse model is associated with increased splenic interleukin-2-producing CD4 T-cell frequency post-vaccination. Immunology 143:661–669PubMedPubMedCentralCrossRefGoogle Scholar
- 27.Hu Z, Wang J, Wan Y, Zhu L, Ren X, Qiu S, Ren Y, Yuan S, Ding X, Chen J, Qiu C, Sun J, Zhang X, Xiang J, Qiu C, Xu J (2014) Boosting functional avidity of CD8+ T cells by vaccinia virus vaccination depends on intrinsic T-cell MyD88 expression but not the inflammatory milieu. J Virol 88:5356–5368PubMedPubMedCentralCrossRefGoogle Scholar
- 29.You Q, Wu Y, Wu Y, Wei W, Wang C, Jiang D, Yu X, Zhang X, Wang Y, Tang Z, Jiang C, Kong W (2012) Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis. Int J Infect Dis 16:e816–e825PubMedCrossRefGoogle Scholar
- 33.Skinner MA, Wedlock DN, de Lisle GW, Cooke MM, Tascon RE, Ferraz JC, Lowrie DB, Vordermeier HM, Hewinson RG, Buddle BM (2005) The order of prime-boost vaccination of neonatal calves with Mycobacterium bovis BCG and a DNA vaccine encoding mycobacterial proteins Hsp65, Hsp70, and Apa is not critical for enhancing protection against bovine tuberculosis. Infect Immun 73:4441–4444PubMedPubMedCentralCrossRefGoogle Scholar
- 34.Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381:1021–1028PubMedPubMedCentralCrossRefGoogle Scholar
- 36.Verreck F, Tchilian EZ, Vervenne R, Sombroek CC, Kondova I, Eissen OA, Sommandas V, van der Werff NM, Verschoor E, Braskamp G, Bakker J, Langermans J, Heidt PJ, Ottenhoff T, van Kralingen KW, Thomas AW, Beverley P, Kocken C (2017) Variable BCG efficacy in rhesus populations: pulmonary BCG provides protection where standard intra-dermal vaccination fails. Tuberculosis (Edinb) 104:46–57CrossRefGoogle Scholar
- 37.Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV (2003) Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of Bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171:1602–1609PubMedCrossRefGoogle Scholar
- 38.Florido M, Muflihah H, Lin L, Xia Y, Sierro F, Palendira M, Feng CG, Bertolino P, Stambas J, Triccas JA, Britton WJ (2018) Pulmonary immunization with a recombinant influenza A virus vaccine induces lung-resident CD4(+) memory T cells that are associated with protection against tuberculosis. Mucosal Immunol 11:1743–1752PubMedCrossRefGoogle Scholar
- 39.Perdomo C, Zedler U, Kuhl AA, Lozza L, Saikali P, Sander LE, Vogelzang A, Kaufmann SH, Kupz A (2016) Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis. MBIO 7. https://doi.org/10.1128/mBio.01686-16
- 40.Bull NC, Stylianou E, Kaveh DA, Pinpathomrat N, Pasricha J, Harrington-Kandt R, Garcia-Pelayo MC, Hogarth PJ, McShane H (2019) Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1(+) KLRG1(-) CD4(+) T cells. Mucosal Immunol 12:555–564PubMedCrossRefGoogle Scholar
- 41.D'Souza S, Rosseels V, Romano M, Tanghe A, Denis O, Jurion F, Castiglione N, Vanonckelen A, Palfliet K, Huygen K (2003) Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun 71:483–493PubMedPubMedCentralCrossRefGoogle Scholar
- 45.Rosseels V, Marche S, Roupie V, Govaerts M, Godfroid J, Walravens K, Huygen K (2006) Members of the 30- to 32-kilodalton mycolyl transferase family (Ag85) from culture filtrate of Mycobacterium avium subsp. paratuberculosis are immunodominant Th1-type antigens recognized early upon infection in mice and cattle. Infect Immun 74:202–212PubMedPubMedCentralCrossRefGoogle Scholar
- 50.Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV, Barber DL (2016) CD4 T cell-derived IFN-gamma plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog 12:e1005667. https://doi.org/10.1371/journal.ppat.1005667 CrossRefPubMedPubMedCentralGoogle Scholar